**[investwise]** Glaxo licenses proprietary tech for gene mutations

 

Response Genetics Inc., which makes diagnostic tests for cancer, said Tuesday it had signed a non-exclusive licensing deal with GlaxoSmithKline. Under the agreement, GlaxoSmithKline ( GSK - news -people ) gets limited rights to Response Genetics ( RGDX -news - people )' proprietary technology and diagnostic expertise of gene mutations. Shares of Response Genetics rose 62 cents, or 29 percent, to $2.77 in afternoon trading. The stock earlier reached a 52-week high of $3.25. The terms of the deal were not disclosed. Safe Harbor Statement: Some forward looking statements on projections, estimates, expectations & outlook are included to enable a better comprehension of the Company prospects. Actual results may, however, differ materially from those stated on account of factors such as changes in government regulations, tax regimes, economic developments within India and the countries within which the Company conducts its business, exchange rate and interest rate movements, impact of competing products and their pricing, product demand and supply constraints.   Nothing in this article is, or should be construed as, investment advice.

__._,_.___

Reply to sender | Reply to group | Reply via web post | Start a new topic

Messages in this topic (1)

Recent Activity:

• New Members 8

Visit Your Group

*****************************************
http://in.groups.yahoo.com/group/investwise/

INVESTMENTS IN INDIA
We are low-risk, long-term investors. 

Stocks, mutual funds and the entire investment gamut.  Only financing/investment avenues in India will be discussed. 

For any assistance, questions or improvement ideas, contact investwise-owner@yahoogroups.co.in

****************************************************************

NEW! ==== Check our LINKS and FILES sections for a world of information. REGULARLY UPDATED.

NEW! ==== Check "Tracklist" in Links and Files sections for Investment Ideas.

****************************************************************

Switch to: Text-Only, Daily Digest • Unsubscribe • Terms of Use

.

__,_._,___